Vertex Pharmaceuticals (NasdaqGS:VRTX) is reassessing its pain management program after disappointing FDA label discussions ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is among the most profitable healthcare stocks to buy. On January 26, UBS ...

Reporting season for the December quarter has come to an end, and these five ASX-listed gold developers are making big ...

China-based biologics CDMO WuXi Biologics (HKEX: 2269) has signed a license and research services agreement with US biotech Vertex Pharmaceuticals (Nasdaq: VRTX) covering a preclinical trispecific ...

CRISPR Therapeutics heads into Q4 earnings with rising Casgevy sales, collaboration revenues from Vertex, and a history of beating estimates.

Jupiter Endovascular completes enrollment in a pivotal trial of its Vertex system with Transforming Fixation technology for pulmonary embolectomy.

AMD is hiring a Senior AI/ML Lead in Hyderabad to lead the design, development, deployment, and optimization of AI/ML ...

Rep. Jake Auchincloss of Massachusetts said the Commissioner’s National Priority Voucher program did not receive congressional backing. The FDA has also not yet made disclosures for eight senior ...

Description: Honey finds coupons with one click. Thanks to Honey for sponsoring! Keyboard build (affiliate links below) ...

Detailed price information for Satellos Bioscience Inc (MSCLF) from The Globe and Mail including charting and trades.

Miles Andrews, BSc (Hons), BMBS (Hons), FRACP, PhD, Medical Oncologist and Senior Research Fellow at the Alfred Hospital and Monash University, Melbourne, Australia; co-author of the NADINA study.

Agomab Therapeutics and SpyGlass Pharma secured a combined $350 million in two separate initial public offerings on Thursday ...